Scientists have shown in mice that skin cells re-programmed into brain stem cells, transplanted into the central nervous system, help reduce inflammation and may be able to help repair damage caused by multiple sclerosis (MS).
Our mouse study suggests that using a patient’s reprogrammed cells could provide a route to personalised treatment of chronic inflammatory diseases, including progressive forms of MS
The study, led by researchers at the University of Cambridge, is a step towards developing personalised treatments based on a patient’s own skin cells for diseases of the central nervous system (CNS).
In MS, the body’s own immune system attacks and damages myelin, the protective sheath around nerve fibres, causing disruption to messages sent around the brain and spinal cord. Symptoms are unpredictable and include problems with mobility and balance, pain, and severe fatigue.
Key immune cells involved in causing this damage are macrophages (literally ‘big eaters’), which ordinarily serve to attack and rid the body of unwanted intruders. A particular type of macrophage known as microglia are found throughout the brain and spinal cord – in progressive forms of MS, they attack the CNS, causing chronic inflammation and damage to nerve cells.
Recent advances have raised expectations that diseases of the CNS may be improved by the use of stem cell therapies. Stem cells are the body’s ‘master cells’, which can develop into almost any type of cell within the body. Previous work from the Cambridge team has shown that transplanting neural stem cells (NSCs) – stem cells that are part-way to developing into nerve cells – reduces inflammation and can help the injured CNS heal.
However, even if such a therapy could be developed, it would be hindered by the fact that such NSCs are sourced from embryos and therefore cannot be obtained in large enough quantities. Also, there is a risk that the body will see them as an alien invader, triggering an immune response to destroy them.
A possible solution to this problem would be the use of so-called ‘induced neural stem cells (iNSCs)’ – these cells can be generated by taking an adult’s skin cells and ‘re-programming’ them back to become neural stem cells. As these iNSCs would be the patient’s own, they are less likely to trigger an immune response.
Now, in research published in the journal Cell Stem Cell, researchers at the University of Cambridge have shown that iNSCs may be a viable option to repairing some of the damage caused by MS.
Using mice that had been manipulated to develop MS, the researchers discovered that chronic MS leads to significantly increased levels of succinate, a small metabolite that sends signals to macrophages and microglia, tricking them into causing inflammation, but only in cerebrospinal fluid, not in the peripheral blood.
Transplanting NSCs and iNSCs directly into the cerebrospinal fluid reduces the amount of succinate, reprogramming the macrophages and microglia – in essence, turning ‘bad’ immune cells ‘good’. This leads to a decrease in inflammation and subsequent secondary damage to the brain and spinal cord.
“Our mouse study suggests that using a patient’s reprogrammed cells could provide a route to personalised treatment of chronic inflammatory diseases, including progressive forms of MS,” says Dr Stefano Pluchino, lead author of the study from the Department of Clinical Neurosciences at the University of Cambridge.
“This is particularly promising as these cells should be more readily obtainable than conventional neural stem cells and would not carry the risk of an adverse immune response.”
The research team was led by Dr Pluchino, together with Dr Christian Frezza from the MRC Cancer Unit at the University of Cambridge, and brought together researchers from several university departments.
Dr Luca Peruzzotti-Jametti, the first author of the study and a Wellcome Trust Research Training Fellow, says: “We made this discovery by bringing together researchers from diverse fields including regenerative medicine, cancer, mitochondrial biology, inflammation and stroke and cellular reprogramming. Without this multidisciplinary collaboration, many of these insights would not have been possible.”
The Latest on: Personalised stem cell treatment
[google_news title=”” keyword=”Personalised stem cell treatment” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Personalised stem cell treatment
- Pioneering NHS trial targets brain tumours before surgeryon February 2, 2023 at 9:52 am
“Remnant tumour cells remain growing, potentially even more aggressively ... and encourages others to join our efforts in seeking more effective and personalised treatment strategies to be applied ...
- From vaccines to AI: New weapons in the fight against canceron February 2, 2023 at 6:59 am
Recent scientific and medical advances have added several new weapons to our arsenal, including personalised gene therapy ... to track down and kill cancerous cells, have been one the biggest advances ...
- CuSTOM; Creating a healthier society by accelerating the translation of organoid technologyon February 1, 2023 at 5:19 am
In this interview, we speak to Magdalena Kasendra at the CuSTOM Accelerator, about the organoid technology and how it has the power the revolutionize healthcare.
- What will cancer therapy look like in 2033?on February 1, 2023 at 4:53 am
Labiotech had the opportunity to put the same question to several experts: what is the future of cancer treatment?
- Measuring changes in brain tissue oxygenation for personalized cancer radiotherapyon January 31, 2023 at 1:31 pm
Radiotherapy, which uses high-energy radiation to kill cancer cells, typically follows a dosing and treatment plan based on clinical research to minimize the impact of the radiation on healthy tissues ...
- Technology’s Role In Determining Cancer Treatmenton January 31, 2023 at 2:15 am
By adopting and embracing AI tools, pathologists will benefit from improved efficiency and the ability to participate in directing high-quality care in other parts of the world.
- Measuring Cancer Cell Death to Optimize Treatment Selectionon January 30, 2023 at 4:00 am
Cell death is the most important measure in a cancer laboratory. An in vitro tumor explant testing platform in combination with a repository of test results for cancer cell death assays could be the ...
- J&J, Legend’s cancer cell therapy has early success in key clinical trialon January 27, 2023 at 12:12 pm
The trial is an important test of Carvykti’s potential for earlier use in multiple myeloma and found treatment helped extend progression-free survival over standard regimens.
- The size of skin cancer cells may affect how they respond to treatmenton January 26, 2023 at 9:23 am
LasserreCertain skin cancer cells may differ in how they respond to various treatments according to their size. Better understanding this and how it relates to treatment outcomes could help doctors ...
- Cancer breakthrough as new 'pioneering treatment' gets NHS seal of approvalon January 26, 2023 at 2:41 am
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending the treatment be made routinely available on the NHS for suitable patients.
via Bing News